etidronate has been researched along with Necrosis in 9 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
Excerpt | Relevance | Reference |
---|---|---|
"Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 5.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
"These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
"Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 1.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
"This osteolysis was evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histologic study." | 1.28 | Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. ( Koiso, K; Miyagawa, I; Nemoto, R; Satou, S, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (44.44) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Okada, S | 1 |
Kiyama, T | 1 |
Sato, E | 1 |
Tanaka, Y | 1 |
Oizumi, T | 2 |
Kuroishi, T | 2 |
Takahashi, T | 1 |
Sasaki, K | 2 |
Sugawara, S | 2 |
Endo, Y | 2 |
Funayama, H | 1 |
Yamaguchi, K | 1 |
Yokoyama, M | 1 |
Takahashi, H | 1 |
Yamamoto, M | 1 |
Kumamoto, H | 1 |
Kawamura, H | 1 |
Trullemans, B | 1 |
Bottu, J | 1 |
Van Nieuwenhuyse, JP | 1 |
Caldecourt, MA | 1 |
Cole, AW | 1 |
Kingaby, RO | 1 |
Palmer, TN | 1 |
Hughes, DE | 1 |
Wright, KR | 1 |
Uy, HL | 1 |
Sasaki, A | 1 |
Yoneda, T | 1 |
Roodman, GD | 1 |
Mundy, GR | 1 |
Boyce, BF | 1 |
Creutzig, H | 1 |
Schulz, D | 1 |
Nemoto, R | 1 |
Satou, S | 1 |
Miyagawa, I | 1 |
Koiso, K | 1 |
Daoud, AS | 1 |
Frank, AS | 1 |
Jarmolych, J | 1 |
Fritz, KE | 1 |
Raper, RF | 1 |
Ibels, LS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
9 other studies available for etidronate and Necrosis
Article | Year |
---|---|
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazo | 2013 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
[Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis].
Topics: Adipose Tissue; Calcinosis; Etidronic Acid; Female; Humans; Hypercalcemia; Infant; Kidney Diseases; | 2007 |
Liposome accumulation in chronic ischaemia is dependent on tissue necrosis.
Topics: Animals; Etidronic Acid; Hydrocortisone; Intestines; Ischemia; Liposomes; Male; Necrosis; Pharmaceut | 1984 |
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Survival; Cells, Cultured; Diphosphonates; Etidronic Acid; | 1995 |
[Comparative studies with bone-seeking radiopharmaceuticals on uptake in necrotic tissue].
Topics: Animals; Diphosphonates; Etidronic Acid; Indium; Male; Muscles; Necrosis; Organophosphorus Compounds | 1977 |
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neop | 1991 |
The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on necrosis of atherosclerotic lesions.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Calcium; Cholesterol; Diet, Atherogenic; DNA; Etidronic | 1987 |
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis.
Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid; | 1985 |